corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library item: 20454

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

 

Publication type: Journal Article

Tucker ME
Drug companies lobby against generic versions of biologics
BMJ 2013 Feb 4; 346:
http://www.bmj.com/content/346/bmj.f740


Abstract:

Biotechnology companies have launched a lobbying initiative to try to stop or slow down the introduction of generic versions of expensive biological drugs. State legislatures across the United States are introducing bills that could make it more difficult for doctors to prescribe—and for patients to obtain—cheaper versions of the drugs.

Generic versions of biological drugs are known as biosimilars. The original versions of the biologics include drugs such as rituximab (marketed as Rituxan or MabThera), trastuzumab (Herceptin), and bevacizumab (Avastin). These are among the best selling anticancer drugs in the world. The drugs, which are produced in cell systems, are said to account for about 25% of the US annual drug bill of $320bn (£205bn; €235bn).

Like other generic drugs, biosimilars are designed to be cheaper versions of brand name drugs. But they are created by …

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.

Email a Friend








You are going to have many difficulties. The smokers will not like your message. The tobacco interests will be vigorously opposed. The media and the government will be loath to support these findings. But you have one factor in your favour. What you have going for you is that you are right.
- Evarts Graham
See:
When truth is unwelcome: the first reports on smoking and lung cancer.